Articles By Estel Grace Masangkay

  1. NICE Issues Final Opinion For Alexion's Soliris For aHUS 12/3/2014

    Alexion announced that the National Institute for Health and Care Excellence (NICE) Highly Specialized Technologies Evaluation Committee (EC) has given its final positive recommendation for Soliris (eculizumab) as treatment for patients in England with atypical hemolytic uremic syndrome (aHUS).

  2. FDA Extends Review Of Novartis' Myeloma Drug 12/2/2014

    Novartis announced that the U.S. Food and Drug Administration (FDA) has decided to extend its priority review period for LBH589 (panobinostat) in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma.

  3. Cipla Links With Serum Institute Of India To Market Pediatric Vaccines In EU 12/2/2014

    Indian pharmaceutical firm Cipla announced that its subsidiary Cipla Europe NV has entered into agreement with Serum Institute of India (SII) to distribute pediatric vaccines in the EU.

  4. TapImmune, VGTIF To Test Cancer Vaccines In Phase 2 Trials 11/25/2014

    Immunotherapy company TapImmune and the non-profit biomedical research institute the Vaccine & Gene Therapy Institute of Florida (VGTI Florida) announced that they have entered into collaboration to test TapImmune's proprietary cancer vaccines in Phase 2 clinical trials as treatment for breast and ovarian cancers.

  5. 3SBio Allies With PharmAbcine For Anti-VEGF Tanibirumab 11/25/2014

    China-based biotech firm 3SBio announced that it has signed an exclusive license agreement with clinical stage biotech firm PharmAbcine for Tanibirumab in Greater China and other territories.

  6. IDRI Receives NIH Grant To Develop Thermostable TB Vaccine 11/24/2014

    The Seattle-based Infectious Disease Research Institute (IDRI) announced that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a thermostable tuberculosis vaccine designed to be resistant to damage from temperature changes.

  7. Genzyme, Isis Post Phase 3 Data For Heart Drug Kynamro At AHA 11/24/2014

    Sanofi company Genzyme and its partner Isis Pharmaceuticals presented new two-year data from the Phase 3 extension study of Kynamro at the American Heart Association meeting in Chicago.

  8. Novartis Posts Topline Data For Heart Failure Drug 11/21/2014

    Novartis announced that new analyses from its late-stage study PARADIGM-HF showed that investigational treatment LCZ696 significantly changed the course of disease for heart failure patients.

  9. Pfizer Broadens Access To Injectable Sayana Press Contraceptive 11/19/2014

    Pfizer announced that it has entered into a public-private collaboration to broaden access to its contraceptive, Sayana Press (Depo-Provera (medroxyprogesterone acetate)). The drug is intended for women most in need in the world’s poorest countries.

  10. Geron, Janssen Link To Develop Blood Cancer Drug Imetelstat 11/19/2014

    Clinical stage biopharmaceutical firm Geron reported that it has signed into an exclusive global license and collaboration with Janssen Biotech to jointly develop and market its drug Imetelstat for hematologic malignancies and other therapeutic uses.